Drug or treatment

Teclistamab clinical trials

• 26Clinical trials
• 29Countries

Newest trials

All recruiting trials (26)

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Quadruplet induction plus autologous transplant followed by teclistamab maintenance for plasma cell leukemia

  This phase 2 trial tests whether adding teclistamab as consolidation after autologous stem cell transplant improves overall survival for patients with plasma cell leukemia compared with the standard D-KRd consolidation.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 10 other locations · NCT07605416

• A comparison of JNJ-79635322 and teclistamab in relapsed or refractory multiple myeloma

  This study tests whether JNJ-79635322 works differently from teclistamab in people with relapsed or refractory multiple myeloma who have had prior therapy.

  Recruiting at 173 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 172 other locations · NCT07518186

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• Teclistamab for recurrent or refractory plasmablastic lymphoma

  This early-phase trial tests a bispecific antibody called teclistamab to see if it is safe and usable at different doses for adults whose plasmablastic lymphoma has returned or not responded to previous treatment.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 19 other locations · NCT07332507

• Teclistamab plus daratumumab for newly diagnosed AL amyloidosis

  This tests whether combining teclistamab with daratumumab is safe and helps people newly diagnosed with AL amyloidosis by lowering harmful light chains and protecting organ function.

  Recruiting at 2 sites Phase 2 Columbia University · Boston, Massachusetts and 2 other locations · NCT07110844

• Daratumumab combined with teclistamab or talquetamab for frail adults with newly diagnosed multiple myeloma

  This study will test whether adding teclistamab or talquetamab to daratumumab helps frail adults newly diagnosed with multiple myeloma remain progression-free at 18 months.

  Recruiting at 6 sites Phase 2 European Myeloma Network B.V. · Ascoli Piceno and 28 other locations · NCT07107529

• Teclistamab plus mezigdomide for relapsed or refractory multiple myeloma

  This trial will try a combination of teclistamab and mezigdomide in people with relapsed or refractory multiple myeloma who have had at least two prior therapies including a proteasome inhibitor, an IMiD, and an anti‑CD38 antibody.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07105059

• Daratumumab followed by teclistamab with RVd for newly diagnosed multiple myeloma

  This test tries whether switching from daratumumab plus RVd to teclistamab plus RVd after three treatment cycles is safe for people with newly diagnosed multiple myeloma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07099391

• Teclistamab treatment for newly diagnosed Mayo stage IIIB AL amyloidosis

  This Phase II trial will test teclistamab, an immune therapy, in people with newly diagnosed Mayo stage IIIB AL amyloidosis to see if it controls disease and is safe.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07079423

• T-cell therapies talquetamab and teclistamab to clear minimal residual disease after transplant in newly diagnosed myeloma (ROTATE)

  This tests whether giving talquetamab to patients who are MRD positive after induction and transplant, and switching to teclistamab if MRD doesn't clear, can make them MRD negative.

  Recruiting at 3 sites Phase 2 Yale University · New Haven, Connecticut and 2 other locations · NCT06993675

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Teclistamab treatment for patients with AL Amyloidosis

  This study is testing if a new treatment called teclistamab can help people with AL Amyloidosis who haven't responded well to previous therapies.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06935162

• Low-dose teclistamab for newly diagnosed multiple myeloma patients

  This study tests if a low dose of teclistamab can help newly diagnosed multiple myeloma patients stay in remission after initial treatment.

  Recruiting Phase 2 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, Nuevo León · NCT06758375

• Using teclistamab to treat systemic AL amyloidosis

  This study is testing if teclistamab can help people with systemic AL amyloidosis who haven't responded to other treatments by seeing if it can eliminate harmful plasma cells and improve their health.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT06699394

• Using bispecific T-cell redirectors for first-line treatment in transplant-eligible multiple myeloma patients

  This study is testing if a new combination of treatments can help newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant feel better and improve their outcomes.

  Recruiting Phase 2 North Estonia Medical Centre · Copenhagen and 6 other locations · NCT06505369

• Assessing the effectiveness of teclistamab for multiple myeloma

  This study is testing if teclistamab can help people with relapsed or hard-to-treat multiple myeloma who have already tried at least three other treatments.

  Recruiting at 16 sites Universitaire Ziekenhuizen KU Leuven · Bonheiden, Antwerpen and 16 other locations · NCT06477783

• Testing a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments, iberdomide and teclistamab, to see if they can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 16 other locations · NCT06465316

• Outpatient teclistamab treatment plan for relapsed or refractory multiple myeloma

  This pilot will try giving teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient clinic to see if it can be delivered safely and practically while measuring effects on caregivers.

  Recruiting Phase 4 University Health Network, Toronto · Toronto, Ontario · NCT06251076

• Combination treatment for high-risk smoldering multiple myeloma

  This study is testing two different combination treatments to see which one helps people with high-risk smoldering multiple myeloma delay their disease from getting worse.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06100237

• Outpatient treatment for multiple myeloma using teclistamab or talquetamab

  This study is testing if two new treatments, teclistamab and talquetamab, can safely help adults with relapsed or hard-to-treat multiple myeloma when given as outpatient care.

  Recruiting at 16 sites Phase 2 SCRI Development Innovations, LLC · Tucson, Arizona and 16 other locations · NCT05972135

• Examining immune cell responses to teclistamab in multiple myeloma patients

  This study is testing how different immune cells in multiple myeloma patients respond to the treatment teclistamab to see why some people benefit from it while others do not.

  Recruiting at 18 sites University Hospital, Toulouse · Amiens, France and 17 other locations · NCT05945524

• Limited-duration treatment with teclistamab for multiple myeloma

  This study is testing if a short-term treatment with teclistamab can help people with multiple myeloma keep their positive response after standard therapy without needing to stay on treatment continuously.

  Recruiting at 5 sites Phase 2 Abramson Cancer Center at Penn Medicine · Little Rock, Arkansas and 4 other locations · NCT05932680

• Combination treatment for newly diagnosed multiple myeloma patients

  This study is testing a new combination treatment for people with newly diagnosed multiple myeloma to see if it can be a safer and more effective alternative to traditional high-dose therapy and stem cell transplants.

  Recruiting at 11 sites Phase 2 University of Heidelberg Medical Center · Berlin and 10 other locations · NCT05695508

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

Quick answers

How many clinical trials of Teclistamab are recruiting right now?

26, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in United States (15 trials), China (6 trials), Germany (3 trials), Canada (3 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 15, Phase 1: 3, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →